Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Breakthrough Therapy Designation granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism (HI) Ersodetug continues to advance in ...
InvestmentNews31m
Next-gen leadership as $750M wealth firm transitions to 100% employee owned
In the decades since Dennis Pettinelli founded Pettinelli Financial Partners it has grown to $750 million in assets under management for more than 500 advisory clients. But a multi-year plan for ...